Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,524.00    0.00 (0.00%)
Bid:
1,100.00
Ask:
2,200.00
Spread: 1,100.00 (100.00%)
Market Cap: £3.21b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
22nd Apr 20164:22 pmRNSDirector/PDMR Shareholding
20th Apr 20164:00 pmRNSDirector/PDMR Shareholding
19th Apr 20164:14 pmRNSDirector/PDMR Shareholding
19th Apr 201612:57 pmRNSDirector/PDMR Shareholding
12th Apr 201610:02 amRNSDirector/PDMR Shareholding
8th Apr 20167:00 amRNSUpdate on ANDA for Generic Advair Diskus®
8th Apr 20167:00 amRNSPortfolio Update - VR315 US
7th Apr 20164:08 pmRNSDirector/PDMR Shareholding
7th Apr 201611:41 amRNSAnnual Information Update
7th Apr 201610:54 amRNSAnnual Financial Report
6th Apr 20164:11 pmRNSBlocklisting Interim Review
5th Apr 20164:13 pmRNSDirector/PDMR Shareholding
31st Mar 20165:37 pmRNSDirector/PDMR Shareholding
29th Mar 20169:36 amRNSDirector/PDMR Shareholding
21st Mar 20162:54 pmRNSDirector/PDMR Shareholding
17th Mar 20163:25 pmRNSDirector/PDMR Shareholding
16th Mar 20167:00 amRNSFinal Results
3rd Mar 20169:25 amRNSNotice of Results
29th Feb 20162:01 pmRNSHolding(s) in Company
29th Feb 20161:59 pmRNSHolding(s) in Company
29th Feb 20161:47 pmRNSTotal Voting Rights
29th Feb 20161:46 pmRNSRoxane Acquisition Close
22nd Feb 20169:52 amRNSDirectorate Change
19th Feb 201612:55 pmRNSEGM Statement
11th Feb 201612:43 pmRNSHolding(s) in Company
11th Feb 201612:19 pmRNSCirc re. Roxane Acquisition
10th Feb 201610:38 amRNSHikma Analyst and Investor Call
10th Feb 20167:00 amRNSCirc re. Roxane Acquisition
22nd Jan 20162:04 pmRNSCirc re. Roxane Acquisition and EGM
7th Jan 201611:08 amRNSTotal Voting Rights
24th Dec 20157:52 amRNSShareholders' Agreement and Board Appointment
17th Dec 20159:38 amRNSTotal Voting Rights
3rd Dec 20159:30 amRNSDirector/PDMR Shareholding
25th Nov 20158:45 amRNSHikma announces sale of Ben Venue manufacturing
24th Nov 20157:00 amRNSHolding(s) in Company
18th Nov 20157:00 amRNSResolution to FDA Warning Letter
16th Nov 20153:04 pmRNSHolding(s) in Company
11th Nov 20154:16 pmRNSHolding(s) in Company
10th Nov 20152:43 pmRNSHolding(s) in Company
2nd Nov 20157:00 amRNSTrading Statement
22nd Oct 20157:00 amRNSBlock Listing of Share
19th Oct 201511:11 amRNSHolding(s) in Company
12th Oct 201510:25 amRNSBlocklisting Interim Review
8th Oct 20154:10 pmRNSTotal Voting Rights
18th Sep 20152:40 pmRNSAudit Tender
16th Sep 20154:08 pmRNSTotal Voting Rights
11th Sep 20153:47 pmRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSHikma agrees to acquire EIMC United Pharmaceutical
27th Aug 20154:02 pmRNSDirector/PDMR Shareholding
27th Aug 20153:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.